Peripheral T cell expansion predicts tumour infiltration and clinical response

Thomas D. Wu (), Shravan Madireddi, Patricia E. de Almeida, Romain Banchereau, Ying-Jiun J. Chen, Avantika S. Chitre, Eugene Y. Chiang, Hina Iftikhar, William E. O’Gorman, Amelia Au-Yeung, Chikara Takahashi, Leonard D. Goldstein, Chungkee Poon, Shilpa Keerthivasan, Denise E. de Almeida Nagata, Xiangnan Du, Hyang-Mi Lee, Karl L. Banta, Sanjeev Mariathasan, Meghna Das Thakur, Mahrukh A. Huseni, Marcus Ballinger, Ivette Estay, Patrick Caplazi, Zora Modrusan, Lélia Delamarre, Ira Mellman, Richard Bourgon and Jane L. Grogan ()
Additional contact information
Thomas D. Wu: Genentech, Inc.
Shravan Madireddi: Genentech, Inc.
Patricia E. de Almeida: Genentech, Inc.
Romain Banchereau: Genentech, Inc.
Ying-Jiun J. Chen: Genentech, Inc.
Avantika S. Chitre: Genentech, Inc.
Eugene Y. Chiang: Genentech, Inc.
Hina Iftikhar: Genentech, Inc.
William E. O’Gorman: Genentech, Inc.
Amelia Au-Yeung: Genentech, Inc.
Chikara Takahashi: Genentech, Inc.
Leonard D. Goldstein: Genentech, Inc.
Chungkee Poon: Genentech, Inc.
Shilpa Keerthivasan: Genentech, Inc.
Denise E. de Almeida Nagata: Genentech, Inc.
Xiangnan Du: Genentech, Inc.
Hyang-Mi Lee: Genentech, Inc.
Karl L. Banta: Genentech, Inc.
Sanjeev Mariathasan: Genentech, Inc.
Meghna Das Thakur: Genentech, Inc.
Mahrukh A. Huseni: Genentech, Inc.
Marcus Ballinger: Genentech, Inc.
Ivette Estay: Genentech, Inc.
Patrick Caplazi: Genentech, Inc.
Zora Modrusan: Genentech, Inc.
Lélia Delamarre: Genentech, Inc.
Ira Mellman: Genentech, Inc.
Richard Bourgon: Genentech, Inc.
Jane L. Grogan: ArsenalBio

Nature, 2020, vol. 579, issue 7798, 274-278

Abstract: Abstract Despite the resounding clinical success in cancer treatment of antibodies that block the interaction of PD1 with its ligand PDL11, the mechanisms involved remain unknown. A major limitation to understanding the origin and fate of T cells in tumour immunity is the lack of quantitative information on the distribution of individual clonotypes of T cells in patients with cancer. Here, by performing deep single-cell sequencing of RNA and T cell receptors in patients with different types of cancer, we survey the profiles of various populations of T cells and T cell receptors in tumours, normal adjacent tissue, and peripheral blood. We find clear evidence of clonotypic expansion of effector-like T cells not only within the tumour but also in normal adjacent tissue. Patients with gene signatures of such clonotypic expansion respond best to anti-PDL1 therapy. Notably, expanded clonotypes found in the tumour and normal adjacent tissue can also typically be detected in peripheral blood, which suggests a convenient approach to patient identification. Analyses of our data together with several external datasets suggest that intratumoural T cells, especially in responsive patients, are replenished with fresh, non-exhausted replacement cells from sites outside the tumour, suggesting continued activity of the cancer immunity cycle in these patients, the acceleration of which may be associated with clinical response.

Date: 2020
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41586-020-2056-8 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:579:y:2020:i:7798:d:10.1038_s41586-020-2056-8

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/s41586-020-2056-8

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().